New UPDATE: Following our posting of this blog post, ESI mailed letters (dated 6/25/20) to pharmacies that announced the temporary suspension of recoupment actions, as ordered by the Defense Health Agency (DHA). These letters were likely received by affected pharmacies as of 6/29/20. Read an updated whitepaper by Brown & Fortunato, P.C. on the suspension notice and what it means to you. Their original whitepaper at the bottom of this blog post provides additional important information about this serious issue.
In this whitepaper from the attorneys at Brown & Fortunato, P.C., find out what pharmacy owners can do if you have received a letter from ESI on recoupment for compound drug claims submitted in 2015.
Recommendations for pharmacists receiving such ESI correspondence, dated April 7, 2020, are to submit a request for Administrative Review (“Review”) to be received by ESI no later than June 30, 2020, and submit all supporting documentation to be received by ESI no later than August 30, 2020.
The balance of the whitepaper discusses the options for pharmacies as they respond to this ESI letter as well as reasons to seek legal counsel on this serious matter.
If you have questions or require assistance from Sykes & Company, P.A., don’t hesitate to contact us at ASK SYKES. We can advise you on helpful resources.